Rxo (RXO) Equity Average (2022 - 2025)
Historic Equity Average for Rxo (RXO) over the last 4 years, with Q4 2025 value amounting to $1.6 billion.
- Rxo's Equity Average fell 438.11% to $1.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.6 billion, marking a year-over-year decrease of 438.11%. This contributed to the annual value of $1.6 billion for FY2025, which is 4292.84% up from last year.
- Per Rxo's latest filing, its Equity Average stood at $1.6 billion for Q4 2025, which was down 438.11% from $1.6 billion recorded in Q3 2025.
- Rxo's 5-year Equity Average high stood at $1.6 billion for Q4 2024, and its period low was $580.5 million during Q2 2024.
- Its 4-year average for Equity Average is $1.0 billion, with a median of $865.5 million in 2022.
- As far as peak fluctuations go, Rxo's Equity Average tumbled by 3160.02% in 2023, and later skyrocketed by 17567.57% in 2024.
- Rxo's Equity Average (Quarter) stood at $865.5 million in 2022, then tumbled by 31.6% to $592.0 million in 2023, then skyrocketed by 175.68% to $1.6 billion in 2024, then dropped by 4.38% to $1.6 billion in 2025.
- Its Equity Average was $1.6 billion in Q4 2025, compared to $1.6 billion in Q3 2025 and $1.6 billion in Q2 2025.